Advances in the design and synthesis of prazosin derivatives over the last ten years

Expert Opinion on Therapeutic Targets

Volumn 15, Issue 12, 2011, Pages 1405-1418

  Desiniotis, Andreas ^a   Kyprianou, Natasha ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

adrenoceptors; benign prostate hyperplasia; cancer therapy; heart failure; prazosin; quinazoline based derivatives

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; DOXAZOSIN; ERLOTINIB; GEFITINIB; PRAZOSIN; PRAZOSIN DERIVATIVE; QUINAZOLINE DERIVATIVE; TAMSULOSIN; TERAZOSIN; UNCLASSIFIED DRUG;

BLADDER; BLADDER NECK; CANCER GROWTH; CANCER INHIBITION; CARCINOMA; DRUG ACTIVITY; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; METASTASIS; NONHUMAN; PROSTATE; REVIEW;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; DRUG DESIGN; HUMANS; HYPERTENSION; MALE; PRAZOSIN; PROSTATIC HYPERPLASIA; RECEPTORS, ADRENERGIC; RECEPTORS, ADRENERGIC, ALPHA-1; URINARY BLADDER NECK OBSTRUCTION;

EID: 83655165092     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2011.641534     Document Type: Review

References (98)

1. Jensen BC, O'Connell TD, Simpson PC. Alpha-1-adrenergic receptors: Targets for agonist drugs to treat heart failure. J MolCell Cardiol 2011;51:518-28
2. Cotecchia S. The alpha1-adrenergic receptors: Diversity of signaling networks and regulation. J Recept Signal Transduct Res 2010;15:410-19
3. Hwa J, Graham RM, Perez DM. Identification of critical determinants of alpha1-adrenergic receptor subtype selective agonist binding. J. Biol. Chem. 1995;270:23189-95
4. Civantos Calzada B, Aleixandre de Artinano A. Alpha-adrenoceptor subtypes. Pharmacol Res 2001;44:195-208 (Pubitemid 32889462)
5. Iwaki K, Sukhatme VP, Shubeita HE, Chien KR. alpha- and beta-adrenergic stimulation induces distinct patterns of immediate early gene expression in neonatal rat myocardial cells. Fos/jun expression is associated with sarcomere assembly; egr-1 induction is primarily an alpha1-mediated response. J. Biol. Chem. 1990;265:13809-17
6. Knowlton KU, Michel MC, Itani M, et al. The alpha1A-adrenergic receptor subtype mediates biochemical, molecular, and morphologic features of cultured myocardial cell hypertrophy. J. Biol. Chem. 1993;268:15374-80 (Pubitemid 23222024)
7. Michelotti GA, Price DT, Schwinn DA. alpha1-adrenergic receptor regulation: Basic science and clinical implications. Pharmacol. Ther. 2000;88:281-309 (Pubitemid 32406055)
8. Ramirez MT, Sah VP, Zhao XL., et al. The MEKK-JNK pathway is stimulated by alpha1-adrenergic receptor and ras activation and is associated with in vitro and in vivo cardiac hypertrophy. J. Biol. Chem. 1997;272:14057-61 (Pubitemid 27232807)
9. Boluyt MO, Zheng JS, Younes A, et al. Rapamycin inhibits alpha1-adrenergic receptor-stimulated cardiac myocyte hypertrophy but not activation of hypertrophy-associated genes. Evidence for involvement of p70 s6 kinase. Circ Res 1997;81:176-86 (Pubitemid 27342484)
10. Kimura M, Ogihara M. Stimulation by transforming growth factor-alpha of DNA synthesis and proliferation of adult rat hepatocytes in primary cultures: Modulation by alpha- and beta-adrenoceptor agonists. J Pharmacol Exp Ther 1999;291:171-80 (Pubitemid 29451587)
11. Nguyen VA, Gao B. Cross-talk between alpha1B-adrenergic receptor (alpha1BAR) and interleukin-6 (IL-6) signaling pathways. Activation of alpha1BAR inhibits il-6-activated STAT3 in hepatic cells by a p42/44 mitogen-activated protein kinase-dependent mechanism. J. Biol. Chem. 1999;274:35492-8 (Pubitemid 129512842)
12. Lin RZ, Chen J, Hu ZW, Hoffman BB. Phosphorylation of the cAMP response element-binding protein and activation of transcription by alpha1 adrenergic receptors. J. Biol. Chem. 1998;273:30033-8 (Pubitemid 28510022)
13. Pennefather JN, Lau WA, Mitchelson F, Ventura S. The autonomic and sensory innervation of the smooth muscle of the prostate gland: A review of pharmacological and histological studies. J Auton Pharmacol 2000;20:193-206 (Pubitemid 34211031)
14. 2+-permeable cationic channels in LNCaP human prostate cancer epithelial cells. J Physiol 2003;548:823-36 (Pubitemid 36603302)
15. 2+ entry and proliferation of prostate cancer epithelial cells. Cancer Res 2006;66:2038-47
16. Shi T, Gaivin RJ, McCune DF, et al. Dominance of the alpha1B-adrenergic receptor and its subcellular localization in human and tramp prostate cancer cell lines. J Recept Signal Transduct Res 2007;27-27-45
17. Park SY, Kang JH, Jeong KJ, et al. Norepinephrine induces VEGF expression and angiogenesis by a hypoxia-inducible factor-1alpha protein-dependent mechanism. Int J Cancer 2011;128:2306-16
18. Walden PD, Gerardi C, Lepor H. Localization and expression of the alpha1A, alpha1B and alpha1D-adrenoceptors in hyperplastic and non-hyperplastic human prostate. J Urol 1999;161:635-40
19. Kaplan SA. Current role of alpha-blockers in the treatment of benign prostatic hyperplasia. BJU Int 2008;102(Suppl 2):3-7
20. Antonello A, Hrelia P, Leonardi A, et al. Design, synthesis, and biological evaluation of prazosin-related derivatives as multipotent compounds. J Med Chem 2005;48:28-31 (Pubitemid 40105246)
21. Boyle P, Napalkov P. The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension. Scand J Urol Nephrol Suppl 1995;168:7-12
22. Cohen BM. Prazosin hydrochloride (cp- 12,299-1), an oral anti-hypertensive agent: Preliminary clinical observations in ambulatory patients. J Clin Pharmacol J New Drugs 1970;10:408-17
23. Brogden RN, Heel RC, Speight TM, Avery GS. Prazosin: A review of its pharmacological properties and therapeutic efficacy in hypertension. Drugs 1977;14:163-97 (Pubitemid 8319383)
24. Stokes GS, Marwood JF. Review of the use of alpha-adrenoceptor antagonists in hypertension. Methods Find Exp Clin Pharmacol 1984;6:197-204 (Pubitemid 14115680)
25. Taylor SH. Clinical pharmacotherapeutics of doxazosin. Am. J. Med 1989;87:2S-11S (Pubitemid 19208767)
26. Pool JL, Taylor AA, Nelson EB. Review of the effects of doxazosin, a new selective alpha 1-adrenergic inhibitor, on lipoproteins in patients with essential hypertension. Am. J. Med 1989;87:57S-61S (Pubitemid 19208775)
27. Fulton B, Wagstaff AJ, Sorkin EM. Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs 1995;49:295-320
28. Wilde MI, Fitton A, Sorkin EM. Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs Aging 1993;3:258-77
29. Wilde MI, Fitton A, McTavish D. Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs 1993;45:410-29 (Pubitemid 23104126)
30. McKeage K, Plosker GL. Alfuzosin: A review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs 2002;62:633-53 (Pubitemid 34264032)
31. Nickel JC. Role of alpha1-blockers in chronic prostatitis syndromes. BJU Int 2008;101(Suppl 3):11-16 (Pubitemid 351328801)
32. Kyprianou N, Litvak JP, Borkowski A, et al. Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. J Urol 1998;159:1810-15 (Pubitemid 29190702)
33. Kyprianou N, Benning CM. Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. Cancer Res 2000;60:4550-5 (Pubitemid 32103639)
34. Yang G, Timme TL, Park SH, et al. Transforming growth factor beta 1 transduced mouse prostate reconstitutions: II. Induction of apoptosis by doxazosin. Prostate 1997;33:157-63 (Pubitemid 27509415)
35. Anglin IE, Glassman DT, Kyprianou N. Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: Mechanistic significance of the quinazoline component. Prostate Cancer Prostatic Dis 2002;5:88-95 (Pubitemid 34777889)
36. Kyprianou N, Tu H, Jacobs SC. Apoptotic versus proliferative activities in human benign prostatic hyperplasia. Hum Pathol 1996;27:668-75 (Pubitemid 26240318)
37. Tahmatzopoulos A, Kyprianou N. Apoptotic impact of alpha1-blockers on prostate cancer growth: A myth or an inviting reality? Prostate 2004;59:91-100 (Pubitemid 38387846)
38. Xu K, Wang X, Ling PM, et al. The alpha1-adrenoceptor antagonist terazosin induces prostate cancer cell death through a p53 and rb independent pathway. Oncol Rep 2003;10:1555-60
39. Pan SL, Guh JH, Huang YW, et al. Identification of apoptotic and antiangiogenic activities of terazosin in human prostate cancer and endothelial cells. J Urol 2003;169:724-9
40. Keledjian K, Borkowski A, Kim G, et al. Reduction of human prostate tumor vascularity by the alpha1-adrenoceptorantagonist terazosin. Prostate 2001;48:71-8 (Pubitemid 32613870)
41. Fernando MA, Heaney AP. alpha1-adrenergic receptor antagonists: novel therapy for pituitary adenomas. Mol Endocrinol 2005;19:3085-96 (Pubitemid 41697723)
42. Hui H, Fernando MA, Heaney AP. The alpha1-adrenergic receptor antagonist doxazosin inhibits EGFR and NF-kappaB signalling to induce breast cancer cell apoptosis. Eur J Cancer 2008;44:160-6 (Pubitemid 350256942)
43. Beduschi MC, Beduschi R, Oesterling JE. Alpha-blockade therapy for benign prostatic hyperplasia: From a nonselective to a more selective alpha1A-adrenergic antagonist. Urology 1998;51:861-72 (Pubitemid 28240842)
44. Dunn CJ, Matheson A, Faulds DM. Tamsulosin: A review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. Drugs Aging 2002;19:135-61 (Pubitemid 34494035)
45. Michel MC, Flannery MT, Narayan P. Worldwide experience with alfuzosin and tamsulosin. Urology 2001;58:508-16 (Pubitemid 32904489)
46. Rosini M, Bolognesi ML, Giardina D, et al. Recent advances in alpha1-adrenoreceptor antagonists as pharmacological tools and therapeutic agents. Curr Top Med Chem 2007;7:147-62 (Pubitemid 46062387)
47. Kawabe K, Yoshida M, Homma Y. Silodosin, a new alpha1A-adrenoceptor- selective antagonist for treating benign prostatic hyperplasia: Results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int 2006;98:1019-24 (Pubitemid 44536452)
48. Rossi M, Roumeguere T. Silodosin in the treatment of benign prostatic hyperplasia. Drug Des Devel Ther 2010;4:291-7
49. Yokoyama O, Ito H, Aoki Y, et al. Selective alpha1A-blocker improves bladder storage function in rats via suppression of C-fiber afferent activity. World J Urol 2010;28:609-14
50. Chapple CR, Montorsi F, Tammela TL, et al. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: Results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in europe. Eur Urol 2011;59:342-52
51. Lepor H, Hill LA. Silodosin for the treatment of benign prostatic hyperplasia: Pharmacology and cardiovascular tolerability. Pharmacotherapy 2010;30:1303-12
52. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7:2958-70 (Pubitemid 32963812)
53. Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 2010;7:493-507
54. Garofalo A, Goossens L, Lemoine A, et al. Quinazoline-urea, new protein kinase inhibitors in treatment of prostate cancer. J Enzyme Inhib Med Chem 2010;25:158-71
55. Garofalo A, Goossens L, Baldeyrou B, et al. Design, synthesis, and DNA-binding of N-alkyl(anilino) quinazoline derivatives. J Med Chem 2010;53:8089-103
56. Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005;65:4389-400 (Pubitemid 40775678)
57. Burger RA. Overview of anti-angiogenic agents in development for ovarian cancer. Gynecol Oncol 2011;121:230-8
58. Lindsay CR, MacPherson IR, Cassidy J. Current status of cediranib: The rapid development of a novel anti-angiogenic therapy. Future Oncol 2009;5:421-32
59. Ulahannan SV, Brahmer JR. Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer. Cancer Invest 2011;29:325-37
60. Huynh H. Molecularly targeted therapy in hepatocellular carcinoma. Biochem Pharmacol 2010;80:550-60
61. Ansari J, Glaholm J, McMenemin R, et al. Recent advances and future directions in the management of metastatic renal cell carcinoma. Anticancer Agents Med Chem 2010;10:225-35
62. Huynh H. Tyrosine kinase inhibitors to treat liver cancer. Expert Opin Emerg Drugs 2010;15:13-26
63. Aragon-Ching JB, Dahut WL. VEGF inhibitors and prostate cancer therapy. Curr Mol Pharmacol 2009;2:161-8
64. Gerstner ER, Duda DG, di Tomaso E, et al. VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. Nat Rev Clin Oncol 2009;6:229-36
65. Wheatley-Price P, Shepherd FA. Targeting angiogenesis in the treatment of lung cancer. J Thorac Oncol 2008;3:1173-84
66. Dietrich J, Wang D, Batchelor TT. Cediranib: Profile of a novel anti-angiogenic agent in patients with glioblastoma. Expert Opin Investig Drugs 2009;18:1549-57
67. Marvania B, Lee PC, Chaniyara R, et al. Design, synthesis and antitumor evaluation of phenyl n-mustard-quinazoline conjugates. Bioorg Med Chem 2011;19:1987-98
68. Kapuriya N, Kakadiya R, Dong H, et al. Design, synthesis, and biological evaluation of novel water-soluble N-mustards as potential anticancer agents. Bioorg Med Chem 2011;19:471-85
69. Chaniyara R, Kapuriya N, Dong H, et al. Novel bifunctional alkylating agents, 5,10-dihydropyrrolo[1,2-b] isoquinoline derivatives, synthesis and biological activity. Bioorg Med Chem 2011;19:275-86
70. Partin JV, Anglin IE, Kyprianou N. Quinazoline-based alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-beta signalling and IkappaBalpha induction. Br J Cancer 2003;88:1615-21 (Pubitemid 36713791)
71. Garrison JB, Kyprianou N. Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptor-mediated pathway. Cancer Res 2006;66:464-72 (Pubitemid 43166055)
72. Shaw YJ, Yang YT, Garrison JB, et al. Pharmacological exploitation of the alpha1-adrenoreceptor antagonist doxazosin to develop a novel class of antitumor agents that block intracellular protein kinase B/Akt activation. J Med Chem 2004;47:4453-62 (Pubitemid 39096833)
73. Garrison JB, Shaw YJ, Chen CS, Kyprianou N. Novel quinazoline-based compounds impair prostate tumorigenesis by targeting tumor vascularity. Cancer Res 2007;67:11344-52 (Pubitemid 350248561)
74. Sakamoto S, Schwarze S, Kyprianou N. Anoikis disruption of focal adhesion-Akt signaling impairs renal cell carcinoma. Eur Urol 2011;59:734-44
75. Sirisoma N, Kasibhatla S, Pervin A, et al. Discovery of 2-chloro-N-(4- methoxyphenyl)-N-methylquinazolin-4- amine (EP128265, MPI-0441138) as a potent inducer of apoptosis with high in vivo activity. J Med Chem 2008;51:4771-9
76. Bauer J, Morley J, Spanton S, et al. Identification, preparation, and characterization of several polymorphs and solvates of terazosin hydrochloride. J Pharm Sci 2006;95:917-28
77. Rosini M, Antonello A, Cavalli A, et al. Prazosin-related compounds. Effect of transforming the piperazinylquinazoline moiety into an aminomethyltetrahydroacridine system on the affinity for alpha1-adrenoreceptors. J Med Chem 2003;46:4895-903 (Pubitemid 37352029)
78. Bolognesi ML, Marucci G, Angeli P, et al. Analogues of prazosin that bear a benextramine-related polyamine backbone exhibit different antagonism toward alpha1-adrenoreceptor subtypes. J. Med. Chem. 2001;44:362-71 (Pubitemid 32113583)
79. Manetti F, Corelli F, Strappaghetti G, Botta M. Arylpiperazines with affinity toward alpha1-adrenergic receptors. Curr Med Chem 2002;9:1303-21 (Pubitemid 34693070)
80. Betti L, Floridi M, Giannaccini G, et al. Design, synthesis, and alpha1-adrenoceptor binding properties of new arylpiperazine derivatives bearing a flavone nucleus as the terminal heterocyclic molecular portion. Bioorg Med Chem 2004;12:1527-35 (Pubitemid 38296543)
81. Minarini A, Budriesi R, Chiarini A, et al. Search for alpha1-adrenoceptor subtypes selective antagonists: Design, synthesis and biological activity of cystazosin, an alpha1D-adrenoceptor antagonist. Bioorg Med Chem Lett 1998;8:1353-8 (Pubitemid 28261301)
82. Giardina D, Gulini U, Massi M, et al. Structure-activity relationships in prazosin-related compounds. 2. Role of the piperazine ring on alpha-blocking activity. J. Med. Chem. 1993;36:690-8 (Pubitemid 23105722)
83. Giardina D, Crucianelli M, Melchiorre C, et al. Receptor binding profile of cyclazosin, a new alpha1B-adrenoceptor antagonist. Eur J Pharmacol 1995;287:13-16
84. Sagratini G, Angeli P, Buccioni M, et al. Synthesis and alpha1-adrenoceptor antagonist activity of derivatives and isosters of the furan portion of (+) -cyclazosin. Bioorg Med Chem 2007;15:2334-45 (Pubitemid 46240916)
85. Giardina D, Martarelli D, Sagratini G, et al. Doxazosin-related alpha1-adrenoceptor antagonists with prostate antitumor activity. J. Med. Chem. 2009;52:4951-4
86. el-Sabbagh OI, Shabaan MA, Kadry HH, Al-Din ES. New octahydroquinazoline derivatives: Synthesis and hypotensive activity. Eur J. Med. Chem. 2010;45:5390-6
87. Bremner JB, Griffith R, Coban B. Ligand design for alpha(1) adrenoceptors. Curr Med Chem 2001;8:607-20
88. MacDougall IJ, Griffith R. Selective pharmacophore design for alpha1-adrenoceptor subtypes. J Mol Graph Model 2006;25:146-57 (Pubitemid 44291551)
89. Nobili S, Landini I, Mazzei T, Mini E. Overcoming tumor multidrug resistance using drugs able to evade P-glycoproteinor to exploit its expression. Med Res Rev 2011;published online 3 March 2011; doi: 10.1002/med.20239
90. Dey S, Ramachandra M, Pastan I, et al. Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc Natl Acad Sci USA 1997;94:10594-9
91. Seidman CE, Hess HJ, Homcy CJ, Graham RM. Synthesis and characterization of a radioiodinated photoaffinity probe for the alpha 1-adrenergic receptor. Hypertension 1984;6-I 7-11
92. Andrus MB, Mettath SN, Song C. A modified synthesis of iodoazidoaryl prazosin. J Org Chem 2002;67:8284-6 (Pubitemid 35332020)
93. Shi Z, Peng XX, Kim IW, et al. Erlotinib (tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res 2007;67:11012-20 (Pubitemid 350145931)
94. Dohse M, Scharenberg C, Shukla S, et al. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos 2010;38:1371-80
95. El-Azab AS, Al-Omar MA, Abdel-Aziz AA, et al. Design, synthesis and biological evaluation of novel quinazoline derivatives as potential antitumor agents: Molecular docking study. Eur J. Med. Chem. 2010;45:4188-98
96. Keledjian K, Garrison JB, Kyprianou N. Doxazosin inhibits human vascular endothelial cell adhesion, migration, and invasion. J Cell Biochem 2005;94:374-88 (Pubitemid 41420315)
97. Sakamoto S, Kyprianou N. Targeting anoikis resistance in prostate cancer metastasis. Mol Aspects Med 2010;31:205-14
98. Kyprianou N. Doxazosin and terazosin suppress prostate growth by inducing apoptosis: Clinical significance. J Urol 2003;169:1520-5 (Pubitemid 36323836)